Clinical Trial Update: Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on the combination of cediranib and olaparib for recurrent cancers of the fallopian tube, ovary, or peritoneum; results have been …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Cediranib (Cediranib)
• Olaparib (Olaparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Fallopian Tube Carcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-03-28